메뉴 건너뛰기




Volumn 185, Issue 1, 2001, Pages 121-127

Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study

(12)  Ness, Roberta B a,b,c,d,e,f,g,h   Soper, David E a,b,c,d,e,f,g,h   Holley, Robert L a,b,c,d,e,f,g,h   Peipert, Jeffrey a,b,c,d,e,f,g,h   Randall, Hugh a,b,c,d,e,f,g,h   Sweet, Richard L a,b,c,d,e,f,g,h   Sondheimer, Steven J a,b,c,d,e,f,g,h   Hendrix, Susan L a,b,c,d,e,f,g,h   Amortegui, Antonio a,b,c,d,e,f,g,h   Trucco, Giuliana a,b,c,d,e,f,g,h   Bass, Debra C a,b,c,d,e,f,g,h   Kelsey, Sheryl F a,b,c,d,e,f,g,h  


Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT;

EID: 0034925420     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.115114     Document Type: Article
Times cited : (46)

References (25)
  • 4
    • 0002029565 scopus 로고    scopus 로고
    • Contraception, contraceptive technology, and STDs
    • Holmes KK, Spading PF, Mardh P-A, et al, editors. Sexually transmitted diseases. New York: McGraw Hill
    • (1999) , pp. 1067-1078
    • Cares W., Jr.1
  • 19
    • 0022653145 scopus 로고
    • Oral contraceptive use modifies the manifestations of pelvic inflammatory disease
    • (1986) BJOG , vol.93 , pp. 619-624
    • Wolner-Hanssen, P.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.